Calliditas gains 100% control of Genkyotex

7 October 2021

Swedish drugmaker Calliditas Therapeutics (STO: CALTX) has now taken full control of France-headquartered Genkyotex (Euronext Paris: GKTX), a leader in NOX inhibition therapies, after the completion of a centralized squeeze out offer to all minority shareholders.

Calliditas first acquired 62.7% of the share capital and voting rights of Genkyotex from Genkyotex' largest shareholders and management team for a cash consideration in 2020, for a transaction value of around $24 million.

Genkyotex’ lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In the fourth quarter of 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase IIb/III design with setanaxib in 318 patients with primary biliary cholangitis (PBC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK